Suramin inhibits the growth of non-small-cell lung cancer cells that express the epidermal growth factor receptor

Oncology (Switzerland)

Volumn 54, Issue 2, 1997, Pages 134-140

  Fujiuchi, Satoru ^a   Ohsaki, Yoshinobu ^a   Kikuchi, Kenjiro ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Epidermal growth factor receptor; Non small cell lung cancer; Suramin

Indexed keywords

CELL SURFACE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; SURAMIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; ONCOGENE C FOS; ONCOGENE C MYC; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION;

ANTICARCINOGENIC AGENTS; BLOTTING, NORTHERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, FOS; GENES, MYC; HUMANS; LUNG NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; RNA, NEOPLASM; SURAMIN; TUMOR CELLS, CULTURED;

EID: 0031054735     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227677     Document Type: Article

References (40)

1. Muir C, Waierhause J, Mack T (eds): Cancer Incidence in Five Continents, Lyon, IARC, 1987.
2. Loehrer PJ, Einhom LH, Greco FA: Cisplatin plus etoposide in small cell lung cancer, Semin Oncol 1988:15:2-8.
3. Siegfried JM: Detection of human lung epithelial cell growth factors produced by a lung carcinoma cell line: Use in culture of primary solid lung tumors, Cancer Res 1987:47:2903-2910.
4. Hult KK, Kaufman D, Gabbay KH, Spencer EM, Lippman ME, Dickson RB: Secretion of an insulin-like growth factor-I-related protein by human breast cancer cells, Cancer Res 1986: 46:4613-4619.
5. Macauly VM, Teale JD, Everard MJ, Joshi GP, Smith IE, Millar JL: Somatomedin C/insulinlike growth factor-1 is a mitogen for human small cell lung cancer, BrJ Cancer 1988:57:91-93.
6. Nikolaos M, Sariban E, Bravo M, Pantazis P, Antoniades HN: Constitutive production of platelet-derived growth factor-like proteins by human prostate carcinoma cell lines, Cancer Res 1988:48:867-871.
7. Bravo M, Vasquez R, Rubio H, Salazar M, Pardo A, Selman M: Production of platelet-derived growth factor by human lung cancer, Res-pirMed 1991;85:479-485.
8. Rozcngurt E, Sinnet SJ, Tayor PJ: Production of PDGF-likc growth factor by breast cancer cell lines, IntJ Cancer 1985:36:247-252.
9. Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fischler A, Minna JD: Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer, Nature 1985:316:823-826.
10. Sporn MB, Todaro GJ: Autocrine secretion and malignant transformation of cells, N Engl J Med 1980;303:878-880.
11. Sainsbury JRC, Famdon JR, Needham GK, Malcolm AJ, Harris AL: Epidernial-growth-factor receptor status as predictor of early recurrence and death from breast cancer, Lancet 1987:8547:1398-1402.
12. Neal DE, Marsh C, Bennett MK, Abel PD, Hall RR, Sainsbury JRC, Harris AL: Epidermal-growth-factor receptors in human bladder cancer: Comparison of invasive and superficial tumours, Lancet 1985:8425:366-368.
13. Tahara E, Sumiyoshi H, Hata J, Yasui W, Ta-niyama K, Havashi T, Nagae S, Sakamoto S: Human epidermal growth factor in gastric carcinoma as a biologic marker of high malignancy, Jpn J Cancer Res 1986:77:145-152.
14. Masui H, Moroyama T, Mendelsohn J: Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypcs, Cancer Res 1986:46:5592-5598.
15. Gill GN, Kawamoto T, Cochet C, Le A, Sato JD, Masui H, McLeod C, Mendelsohn J: Monoclonal ant ¡-epidermal growth factor binding and antagonist of epidermal growth-factor-stimulated tyrosine protein kinase activity, J Biol Chcm 1984:259:7755-7760.
16. Cerny T, Barnes DM, Hasleton P, Barber PV, Healy K, Gullick W, Thatcher N: Expression of epidermal growth factor receptor (EGF-R) in human lung tumours, Br J Cancer 1986:54: 265-269.
17. Hamburger AW, White CP, Brown RW: Effect of epidermal growth factor on proliferation of human tumor cells in soft agar, J Natl Cancer Inst 1981;67:825-830.
18. Carpenter C, Cohen S: Epidermal growth factor, Annu Rev Biochem 1979:48:193-216.
19. Rozcngurt E: Signal transduction pathways in mitogcnesis, BrMed Bull 1989;45:515-528.
20. Carpenter G, Cohen S: Epidermal growth factor, J Biol Chem 1990;265:7709-7712.
21. McCaffrey P, Ran W, Campisi J, Rosner MR: Two independent growth factor-generated signals regulate c-/os and c-myc mRNA levels in Swiss 3T3 cells, J Biol Chcm 1987;262:1442-1445.
22. Coffey RJ, Leof EB, Shipley GD, Moses HL: Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells, J Cell Physiol 1987;132:143-148.
23. Hosang M: Suramin binds to platelet-derived growth factor and inhibits its biological activity, J Cell Biochem 1985;29:265-273.
24. Williams LT, Tremble PM, Lavin MF, Sunday ME: Platelet-derived growth factor receptors form a high-affinity state in membrane preparations, J Biol Chem 1984;259:5287-5294.
25. Poliak M, Richard M: Suramin blockade of insulin-like growth factor I-stimulated proliferation of human osteosarcoma cells, J Natl Cancer Inst 1990;82:1349-1352.
26. DeClercq E: Suramin: A potent inhibitor of the reverse transcriptase of RNA tumor viruses, Cancer Lett 1979:8:9-22.
27. Hensey CE, Boscobonoinik D, Azzi A: Suramin, an anti-cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A, FEBS Lett 1989; 258:156-158.
28. Ono K, Nakanc H, Fukushima M: Differential inhibition of various deoxyribonucleic and ribonucleic acid polymerases by suramin, Eur J Biochem 1988;172:349-353.
29. Bojanowski K, Lelievrc S, Markovits J, Cou-prie J, Jacquemin-Sablon A, Larsen A: Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells, Proc Natl Acad Sci USA 1992,89:3025-3029.
30. Haeder M, Rotsch M, Bepler G, Henning C, Havemann K, Heimann B, Moelling K: Epidermal growth factor receptor expression in human lung cancer cell lines, Cancer Res 1988: 48:1132-1136.
31. Shcrwin SA, Minna JD, Gazdar AF, Todaro GJ: Expression of epidermal and nerve growth factor receptors and soft agar growth factor production by human lung cancer cells, Cancer Res 1981;41:3538-3542.
32. Munson PJ, Rodbard D: LIGAND: A versatile computerized approach for characterization of ligand-binding systems, Anal Biochem 1980; 107:220-239.
33. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ: Isolation of biologically active ribonucleic acid from sources enriched in ribonu-clease, Biochemistry 1979;18:5294-5299.
34. Eriksson AE, Cousens LS, Weaver LH, Matthews BW: Three-dimensional structure of human basic fibroblast growth factor, Proc Natl Acad Sci USA 1991:88:3441-3445.
35. La Rocca RV, Stein CA, Myers CE: Suramin: Prototype of a new generation of antitumor compounds, Cancer Cells 1990;2:106-115.
36. Middaugh CR, Mach H, Burke CJ, Volkin DB, Dabora JM, Tsai PK, Bruner MW, Ryan JA, Marfia KE: Nature of the interaction of growth factors with suramin, Biochemistry 1992:31: 9016-9024.
37. Kim JH, Sherwood ER, Sutkowski DM, Lee C, Kozlowski JM: Inhibition of prostatic tumor cell proliferation by suramin: Alternations in TGF alpha-mediated autocrine growth regulation and cell cycle distribution, J Urol 1991; 146:171-176.
38. Stein CA: Suramin: A novel antineoplastic agent with multiple potential mechanisms of action, Cancer Res 1993;53:2239-2248.
39. Myers C, Cooper M, Stein C, La Rocca R, Walther MM, Weiss G, Chovke P, Dawson N, Steinberg S, Uhrich MM, Cassidy J, Kohler DR, Trepel J, Linehan WM: Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer, J Clin Oncol 1992;10:881-889.
40. Lopez RL, Peters GJ, van Locnen AC, Pizao PE, van Rijswijk REN, Wangstaff J, Pinedo HM: The effect of schedule, protein binding and growth factors on the activity of suramin, IntJ Cancer 1992;51:921-926.